Global Preventive Asthma Drugs Market: Overview
Asthma is a chronic lung disease characterized by narrowing of airways and continual, marked inflammation and in response to specific triggers, which are usually reversible. If the management of the conditions are not done properly, this may elevate the risk of asthma attacks and even medical emergencies. Most, if not all, asthma attacks are preventable, especially in adults. Notwithstanding this fact, world over there is a rising prevalence of asthma, which is closely linked to the severity and mortality of the disease. In particular, this is evident in developed nations such as the U.S.
Preventive drugs for asthma play a crucial role in managing the disease conditions and help pacify the risk of asthma attacks. Drug therapies for asthma have been evolving rapidly, driven by advances in pharmacotherapy of asthma. Research into expanding the various pathophysiologic processes related with asthmatic response and triggers will lead to advanced classes of asthma drugs with less toxicity. Rise in population with higher tobacco consumption and prolonged exposure to smoke of biomass fuels are adding to the prevalence of the disease.
The report offers critical assessment of key growth drivers, prominent trends, recent research and development activities, clinical advances, and the prevailing regulatory framework affecting product development in various countries. The insights help market players devise investment strategies and identify lucrative avenues.
Global Preventive Asthma Drugs Market: Trends and Opportunities
The rise in pollution levels in a number of industrialized nations has led to an increased presence of allergens triggering asthma. This is a key factor driving the demand for preventive asthma drugs. The rising incidence of asthma in various parts of emerging and developed economies, along with the morbidity associated with the disease, is a key factor accentuating the demand for preventive drugs.